跳至主要内容
临床试验/EUCTR2005-003231-46-AT
EUCTR2005-003231-46-AT进行中(未招募)不适用

Changes in hepatic lipid content assessed by MR Spectroscopy in patients with non-alcoholic fatty liver disease (NAFLD) under standard therapy (reduction diet and regular aerobic exercise) with and without lipid lowering therapy - NAFLD

Dept of Internal Medicine IV, Med Uni Vienna0 个研究点目标入组 60 人开始时间: 2005年9月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with elevated liver enzymes and NAFLD (=33% hepatic steatosis) on liver histology in whom other causes of liver disease have been excluded.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • viral hepatitis (A, B, C)
  • autoimmune, genetic, cholestatic liver diseases
  • consumption of >140 grams of alcohol per week
  • regular exercise training (=3 times per week) before begin of the study
  • pregnancy and lactation
  • known hypersensitivity to Ezetimibe
  • Patients currently taking lipid lowering agents
  • -contraindications to MR-Spectroscopy

研究者

发起方
Dept of Internal Medicine IV, Med Uni Vienna

相似试验